Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity
- Author
- Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
- Published
- Fri 25 Jun 2021
- Episode Link
- https://audioboom.com/posts/7893654
Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.
